Physician profile
Jane R Sharp
NPI 1013926633
$4,154.03
in general payments reported to CMS, 2019-2025
22 companies · $183 in 2025
The $183 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $386 · 2020: $58.54 · 2021: $229 · 2022: $381 · 2023: $2,344 · 2024: $572 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,500 · Food and Beverage: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,500.00 |
| Food and Beverage | $599.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,737.51 | 2019-2025 | |
| Exeltis, USA INC. | $193.30 | 2022-2025 | Slynd |
| Myriad Women'S Health, INC. | $138.15 | 2023 | |
| Astellas Pharma US INC | $126.61 | 2023-2024 | Veozah |
| Boston Scientific Corporation | $118.47 | 2019 | |
| Coopersurgical, INC. | $97.23 | 2019-2022 | |
| Myovant Sciences INC. | $92.41 | 2021-2022 | |
| Hologic Sales and Service, LLC | $82.88 | 2021-2022 | |
| Pfizer INC. | $67.73 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $65.93 | 2019-2022 | |
| Therapeuticsmd, INC. | $62.45 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $60.46 | 2021-2023 | |
| Evofem Biosciences, INC. | $55.37 | 2022 | |
| Merck Sharp & Dohme LLC | $45.99 | 2019 | |
| Sumitomo Pharma America, INC. | $39.80 | 2023-2025 | Gemtesa, Myfembree |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Pharmaceuticals INC. | $35.16 | 2021-2022 | |
| Lupin INC. | $29.77 | 2019 | |
| Dexcom, INC. | $26.25 | 2025 | Dexcom G6 Transmitter |
| Daiichi Sankyo INC. | $20.80 | 2023 | Injectafer |
| Agile Therapeutics, INC. | $20.65 | 2022 | |
| Becton, Dickinson and Company | $18.93 | 2020 | |
| Roche Diagnostics Corporation | $18.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Sharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.